BLENREP, generically known as belantamab mafodotin-blmf, is a targeted therapy used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. This innovative medication belongs to a class of drugs known as antibody-drug conjugates (ADCs), which are designed to deliver a potent anti-cancer agent directly to cancer cells. BLENREP specifically targets a protein called BCMA (B-cell maturation antigen) that is commonly found on the surface of myeloma cells. By binding to BCMA, BLENREP delivers a cytotoxic agent directly to the myeloma cells, helping to kill them while sparing healthy cells. This mechanism of action makes BLENREP a valuable option for patients with relapsed or refractory multiple myeloma, particularly for those who have received prior treatments. However, like all medications, BLENREP can cause side effects, and its use is carefully considered by healthcare professionals based on the individual patient's condition and treatment history.